Rhena F U Klar

Longitudinal analysis of cell-free mutated KRAS and CA 19–9 predicts survival following curative resection of pancreatic cancer

M. Boerries, J. Duyster, U. Wittel, 2020, BMC Cancer.

Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma

U. Wittel, L. Braun, S. Fichtner-Feigl, 2021, Scientific Reports.

BRAFΔβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability.

S. Fröhling, M. Boerries, M. Fröhlich, 2023, Science advances.

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition

P. Seidel, P. Wild, T. Brummer, 2021, Cancers.

Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures

U. Wittel, B. Kammerer, S. Lagies, 2020, Cancers.

Development and clinical validation of discriminatory multi-target digital droplet PCR assays for the detection of hot spot KRAS and NRAS mutations in cell-free DNA.

M. Boerries, J. Duyster, U. Wittel, 2020, The Journal of molecular diagnostics : JMD.